Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 14/20 | 0.58 |
| ▸ | MLLT3 | P42568 | 4/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17425964 | 0.81 | MLLT1 (0.44) | MLLT1MLLT3SCN5ADNMT1YEATS2 | |
| SCHEMBL18576503 | 0.80 | MLLT1 (0.45) | MLLT1MLLT3SCN5ADNMT1YEATS2 | |
| SCHEMBL2736776 | 0.74 | DNMT1 (0.46) | MLLT1MLLT3SCN5ADNMT1MAPK14 | |
| SCHEMBL15907160 | 0.72 | MLLT1 (0.40) | MLLT1SCN5APARP15PARP10TNKS2 | |
| SCHEMBL21388565 | 0.72 | MLLT1 (0.41) | MLLT1MLLT3SCN5ADNMT1MAPK14 | |
| SCHEMBL20689916 | 0.72 | DNMT1 (0.42) | MLLT1MLLT3SCN5ADNMT1YEATS2 | |
| SCHEMBL16824464 | 0.70 | KMT2A (0.53) | MLLT1MLLT3YEATS2NAMPT | |
| SCHEMBL21369473 | 0.69 | DNMT1 (0.46) | MLLT1MLLT3SCN5ADNMT1YEATS2 | |
| SCHEMBL15008043 | 0.69 | MAPK14 (0.54) | MLLT1MLLT3SCN5ADNMT1MAPK14 | |
| SCHEMBL5250334 | 0.69 | DNMT1 (0.46) | MLLT1MLLT3SCN5ADNMT1YEATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023077259-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078426-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 上海优理惠生医药有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MLLT1 2749/4885MLLT3 3704/4885SCN5A 3339/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MLLT1 2749/4885MLLT3 3704/4885SCN5A 3339/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | MLLT1 1286/4885MLLT3 282/4885SCN5A 52/4885 |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | MLLT1 3569/4885MLLT3 3055/4885SCN5A 2048/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | MLLT1 593/4885MLLT3 1367/4885SCN5A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.